These findings substantiate the concept that inhibiting the PI3K/AKT/mTOR pathway in GSCs not only impedes tumor proliferation but may also avert recurrence by eliminating therapy-resistant subpopulations (Table 1). Here, PIK3CD is linked to neoplasm.